NCT06837142

A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Taisho Pharmaceutical Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 39 Years
• Healthy volunteers: Accepted

Summary

An open-label, single-center, single-sequence study to evaluate the drug-drud interaction between the CYP3A substrate triazolam and TS-172 (part A) and the potent CYP3A inhibitor itraconazole and TS-172 (part B) in healthy male subjects on their pharmacokinetics, safety and tolerability

Conditions

• Healthy Male Subjects

Interventions

Type	Name	Description
DRUG	Triazolam and TS-172	Oral single administration of triazolam 0.25 mg at single administration phase, followed by a oral single administration of triazolam 0.25 mg and TS-172 20 mg at concomitant administration phase
DRUG	TS-172 and itraconazole	Oral single administrtation of TS-172 20 mg at single administration phase, followed by a oral single administration of TS-172 and itoraconazole 200 mg at concomitant administration phase

Timeline

• Start date: 2025-03-11
• Primary completion: 2025-04-30
• Completion: 2025-04-30
• First posted: 2025-02-20
• Last updated: 2025-05-15

Locations

1 site across 1 country: Japan